| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
105,433 |
55,711 |
$8.95M |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
49,684 |
28,720 |
$7.53M |
| J2315 |
Injection, naltrexone, depot form, 1 mg |
3,868 |
3,518 |
$4.15M |
| 80305 |
|
128,179 |
64,906 |
$1.45M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
20,257 |
14,286 |
$1.17M |
| 80356 |
|
58,765 |
36,718 |
$903K |
| 80364 |
|
58,759 |
36,715 |
$903K |
| 80365 |
|
58,763 |
36,719 |
$903K |
| 80354 |
|
58,765 |
36,718 |
$903K |
| 80358 |
|
58,762 |
36,718 |
$903K |
| 80373 |
|
58,762 |
36,718 |
$903K |
| 80348 |
|
58,766 |
36,715 |
$903K |
| 80370 |
|
56,880 |
36,045 |
$875K |
| 80368 |
|
56,883 |
36,048 |
$875K |
| 80349 |
|
56,883 |
36,048 |
$875K |
| 80366 |
|
56,731 |
35,923 |
$872K |
| 80355 |
|
56,677 |
35,870 |
$871K |
| 80347 |
|
56,673 |
35,866 |
$871K |
| 80357 |
|
56,677 |
35,869 |
$871K |
| 80332 |
|
50,250 |
32,238 |
$773K |
| 80326 |
|
50,251 |
32,238 |
$773K |
| 80359 |
|
50,253 |
32,239 |
$773K |
| 80353 |
|
50,251 |
32,238 |
$773K |
| 80360 |
|
50,250 |
32,239 |
$772K |
| 80345 |
|
45,486 |
29,175 |
$700K |
| 80375 |
|
43,337 |
27,607 |
$663K |
| 99205 |
Prolong outpt/office vis |
3,164 |
3,000 |
$485K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
3,876 |
3,657 |
$465K |
| 80371 |
|
15,432 |
9,501 |
$241K |
| 80372 |
|
15,422 |
9,466 |
$240K |
| 80367 |
|
15,422 |
9,466 |
$240K |
| 80351 |
|
15,383 |
9,499 |
$240K |
| 82075 |
|
11,658 |
9,399 |
$219K |
| Q9992 |
Injection, buprenorphine extended-release (sublocade), greater than 100 mg |
128 |
111 |
$179K |
| 81025 |
|
15,289 |
13,743 |
$117K |
| 99215 |
Prolong outpt/office vis |
843 |
750 |
$98K |
| 99409 |
|
1,280 |
1,208 |
$71K |
| 80376 |
|
3,987 |
2,627 |
$65K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
513 |
376 |
$50K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
512 |
489 |
$42K |
| 80321 |
|
1,681 |
943 |
$19K |
| H0004 |
Behavioral health counseling and therapy, per 15 minutes |
547 |
372 |
$14K |
| H0005 |
Alcohol and/or drug services; group counseling by a clinician |
385 |
232 |
$9K |
| 90833 |
Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) |
304 |
238 |
$7K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
75 |
67 |
$6K |
| H0006 |
Alcohol and/or drug services; case management |
400 |
288 |
$5K |
| H0001 |
Alcohol and/or drug assessment |
177 |
98 |
$5K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
17 |
17 |
$231.24 |
| 90686 |
|
17 |
17 |
$215.64 |
| 96127 |
|
12 |
12 |
$4.24 |
| 99222 |
Initial hospital care, per day, moderate complexity |
45 |
44 |
$0.00 |
| 90791 |
Psychiatric diagnostic evaluation |
84 |
83 |
$0.00 |
| 90832 |
Psychotherapy, 30 minutes with patient |
174 |
162 |
$0.00 |
| 99232 |
Subsequent hospital care, per day, moderate complexity |
117 |
108 |
$0.00 |